The worldwide incidence of cancer will double in the next two decades, from 10 to 20 million. Even there are some advances in surgery, radiotherapy and cytotoxic chemotherapy, the majority of human cancers are difficult to treat. There have been some achievements from use of chemotherapy, but effects of drugs to cure cancer are small. Conventional anticancer drugs use in combination cures some childhood cancers, testicular cancer and lymphomas. Adjuvant chemotherapy improves cure rates of early breast cancer. All chemotherapeutic agents have low therapeutic index, i.e. low ratio of the dose, which causes severe normal tissue toxicity to that causes a substantial degree of antitumor activity. None of the targets of current anticancer drugs are cancer specific: all targets are required by normal cells, especially rapidly proliferating normal cells. There is a hope that new anticancer medicines based on our growing understanding of cancer molecular features, will improve cancer therapy. New targets for drug development are cell cycle regulators, growth factors and their receptors signal transduction intermediates, apoptosis, angiogenesis, metastasis, DNA repair etc. Cancer chemotherapy in the future will be mechanism-oriented e.g. anti-RAS drugs when RAS is mutated, anti-protein tyrosine kinase if c-kit is mutated. The concept of magic bullet will finally be established in the treatment of cancer.